Nitrase Therapeutics
Dr. Probst is the director of chemistry a Nitrome Biosciences, bringing 20 years of pharmaceutical industry experience. Previously he worked at Cor Therapeutics, Elan Pharmaceuticals, Igenica Biotherapeutics, and as a consultant. Dr. Probst was a team member that discovered Betrixaban and designed and synthesized ELND006 and ELND007, experimental treatments for Alzheimer’s disease. He is an author on 27 peer-reviewed journal articles, an inventor on 10 issued US patents and more than a dozen additional patent applications, and a contributor to 11 presentations or posters from scientific meetings. Dr. Probst holds a BS and Ph.D. in chemistry from UCLA and Stanford University, respectively.
This person is not in any offices
Nitrase Therapeutics
1 followers
Nitrase Therapeutics is a pioneering biopharmaceutical company deploying its unique NITROME platform to unlock the therapeutic potential of nitrases, a new class of enzymes that it discovered, to develop a pipeline of therapies against a broad variety of diseases. The medicines that Nitrase Therapeutics is developing will target these enzymes and potentially help slow or halt the progression of a wide variety of diseases in which nitrases and nitro-substrates play a role, including Parkinson’s and cancer. Nitrase Therapeutics (under the former name Nitrome Biosciences) has been widely recognized and has won multiple awards including the prestigious Target Advancement grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF).